FINWIRES · TerminalLIVE
FINWIRES

Applied BioCode Unit Gets US FDA Nod for Respiratory Pathogen Panel

By

-- Applied BioCode's (TPE:6598) US unit has secured a 510(k) clearance from the U.S. FDA for its respiratory pathogen panel, according to a Monday Taiwan Exchange filing.

The approval allows the panel to be used with the BioCode MDx 3000 system alongside Thermo Fisher Scientific's KingFisher extraction platform, adding to existing compatibility with systems from bioMérieux and Roche.

The company said the clearance enables sales of the combined solution in the US, offers labs greater flexibility in extraction systems, and is expected to support its business and financial performance.

Related Articles

Asia

Ashok Leyland's Total Sales Climb 9% in April

Commercial vehicles manufacturer Ashok Leyland (NSE:ASHOKLEY, BOM:500477) total sales rose 9% to 14,646 units in April from 13,421 units sold a year ago, according to a Monday filing to the Indian stock exchanges.During the reported month, total medium and heavy commercial vehicles grew 4% at 8,302 units from 7,960 units a year earlier.Of the total, domestic sales of the commercial vehicles manufacturer were also up 14% year-on-year in April to 14,242 units.The company's shares were up nearly 1% in recent trade.

$BOM:500477$NSE:ASHOKLEY
Equities

Questerre Energy Completes $23.5 Million Sale of Interest in Canadian Assets

Questerre Energy (QEC.OL) completed the divestment of non-operated minority working interest in the Kakwa Central assets in Canada on May 1.The energy technology and innovation company said Monday it sold the assets for cash consideration of $23.5 million, alongside the assumption of decommissioning liabilities and commitments under firm transportation and processing contracts.

$QEC.OL
Asia

Market Chatter: Bank of Korea Deputy Chief Says Time to Consider Rate Hike

Bank of Korea's senior deputy governor Sang-dai said Sunday that it was time to stop rate cuts and start thinking about rate hikes, taking into account persistent inflationary pressures despite measures such as nationwide fuel price caps, Reuters reported Monday.Since April, expectations suggest economic growth will remain close to 2%, while inflation is likely to surpass 2.2%, Ryoo said, backing his claim for rate hikes ahead.In April, the South Korean central bank kept interest rates steady amid increasing uncertainty from Middle East tensions and its possible effect on growth and inflation. Ryoo's remarks followed the country recording its fastest growth in nearly six years in the first quarter, driven by better-than-expected chip exports, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^KOSDAQ$^KS11